Nilutamide is a nonsteroidal anti-androgen newly available for the treatment of prostatic cancer.1 In a case recently reported, it has been considered responsible for an inter­stitial pneumonitis occurring after a treatment of two months (cumulative dose: 12.5 g) and disappearing three months after the drug was withdrawn; in BAL fluid, there was a lymphocytosis (55 [...]

Continue reading " Provocation Test Coupled with Bronchoaiveoiar Lavage in Diagnosis off Drug (Nilutamide): DISCUSSION "

The case we are reporting here is that of a patient whose interstitial pneumonitis seemed to be induced by nilu­tamide, a newly available active drug for prostate cancer treatment. The correlation between variations of BAL cell data sequentially evaluated and the provocation test with this drug would appear to exemplify the possible diagnostic interest in [...]

Continue reading " Provocation Test Coupled with Bronchoaiveoiar Lavage in Diagnosis off Drug (Nilutamide) "

This study shows that, compared with continuous flow TTO, pulsed transtracheal oxygen improves the efficiency of oxygen delivery by a factor of 3:1 while achieving an equivalent Sa02. Previous studies have shown that continuous flow TTO therapy improves the efficiency of oxygen delivery by between 2:1 and 3:1 over continuous flow nasal oxygen therapy. If [...]

Continue reading " Pulsed Nasal and Transtracheal Oxygen Delivery: DISCUSSION continue "

This study demonstrates that the efficiency of nasal oxygen therapy is improved by early delivery of the inspiratory pulse; the Sa02 increases progressively as the delay between the inspiratory signal and the delivery of the pulse is shortened. In contrast, delays in delivery of transtracheal pulses up to 164 ms has no effect on Sa02. [...]

Continue reading " Pulsed Nasal and Transtracheal Oxygen Delivery: DISCUSSION "

The entry data for the subjects in both parts of the study are shown in Tables 1 and 2. The mean age was 65 ± 6 years for the seven subjects in the pulsed nasal oxygen study. Their mean FVC was 1.4 ± 0.3 L and a mean FEW{ was 0.8 ±0.4 L. The mean [...]

Continue reading " Pulsed Nasal and Transtracheal Oxygen Delivery: RESULTS "

Equipment The electronic demand oxygen delivery device used in this study was the Oxymatic (Chad Therapeutics Inc, Chatsworth, CA). We modified the Oxymatic to add a settable delay of 164, 100, 70, 25 or 1 ms between the beginning of inspiratory flow and initiation of the oxygen pulse. In addition, a pre-inspiratory trigger setting was [...]

Continue reading " Pulsed Nasal and Transtracheal Oxygen Delivery: METHODS "

There has been recent interest in increasing the efficiency of oxygen delivery in an effort to im­prove the portability of ambulatory oxygen and to reduce the cost of oxygen therapy. Oxygen-conserving devices designed to meet these needs are TTO cath­eters, electronic pulsed DODS and reservoir cannulas. In addition to oxygen conservation, trans­tracheal oxygen therapy has [...]

Continue reading " Pulsed Nasal and Transtracheal Oxygen Delivery "